Future implications of this study
However, this study in itself has already begun a new conversation regarding personalizing the treatment of cystic fibrosis. Brochiero explained, "by using cells collected from patients, we think that it will be possible to test and predict the efficacy of treatments such as Kalydeco and Orkambi, on cells collected from the patient, in the presence of the bacteria taken from the same patient. We'll also evaluate the ability of the treatments to repair damaged lung tissue. And lastly, we'll work on identifying the most effective molecules, such as bacterial quorum-sensing inhibitors, that can counteract the harmful effect of infections. The ultimate goal is to improve treatments for patients and by doing so, extend their life."
Orkambi and Kalydeco can slow or halt the decreasing function of the lungs, when successful, making increasing the efficacy of the two a powerful tool in treatment. Should the supplements be offered, they are sure to extend the lives of many, as well as make daily life easier due to the alleviation of many symptoms.